{"schema":"hottub-news/prospects/v1","item":{"id":"n_mm4ydohuwbcrwduqtyta","title":"Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach","title_en":null,"url":"https://www.finanznachrichten.de/nachrichten-2026-11/70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm","outlet":"Finanznachrichten.de","published":"2026-11-18T14:24:00Z","sponsored":false,"page":"https://hottub.news/articles/n_mm4ydohuwbcrwduqtyta"},"prospects":[{"name":"Biocon","kind":"organization","role":"named","entity":"wikidata:Q487694","source":"https://www.finanznachrichten.de/nachrichten-2026-11/70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm","note":"In the news: Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach (Finanznachrichten.de, 2026-11-18)","reason":"Named in a headline on 2026-11-18: “Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach” (Finanznachrichten.de)","group":"Organizations","add_url":"https://crm.joinhottub.com/relationships/add#name=Biocon&kind=organization&source=https%3A%2F%2Fwww.finanznachrichten.de%2Fnachrichten-2026-11%2F70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm&entity=wikidata%3AQ487694&note=In%20the%20news%3A%20Biocon%27s%20Pertuzumab%20Receives%20Marketing%20Authorization%20in%20EU%2C%20First%20Biosimilar%20Authorized%20Under%20EMA%27s%20New%20Tailored%20Clinical%20Approach%20%28Finanznachrichten.de%2C%202026-11-18%29","propose":{"name":"Biocon","kind":"organization","reason":"Named in a headline on 2026-11-18: “Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach” (Finanznachrichten.de)","requestId":"news:n_mm4ydohuwbcrwduqtyta:wikidata:Q487694:bee6ec81","sourceUrl":"https://www.finanznachrichten.de/nachrichten-2026-11/70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm","entity":"wikidata:Q487694"}},{"name":"European Medicines Agency","kind":"organization","role":"named","entity":"wikidata:Q130146","source":"https://www.finanznachrichten.de/nachrichten-2026-11/70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm","note":"In the news: Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach (Finanznachrichten.de, 2026-11-18)","reason":"Named in a headline on 2026-11-18: “Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach” (Finanznachrichten.de)","group":"Organizations","add_url":"https://crm.joinhottub.com/relationships/add#name=European%20Medicines%20Agency&kind=organization&source=https%3A%2F%2Fwww.finanznachrichten.de%2Fnachrichten-2026-11%2F70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm&entity=wikidata%3AQ130146&note=In%20the%20news%3A%20Biocon%27s%20Pertuzumab%20Receives%20Marketing%20Authorization%20in%20EU%2C%20First%20Biosimilar%20Authorized%20Under%20EMA%27s%20New%20Tailored%20Clinical%20Approach%20%28Finanznachrichten.de%2C%202026-11-18%29","propose":{"name":"European Medicines Agency","kind":"organization","reason":"Named in a headline on 2026-11-18: “Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach” (Finanznachrichten.de)","requestId":"news:n_mm4ydohuwbcrwduqtyta:wikidata:Q130146:bee6ec81","sourceUrl":"https://www.finanznachrichten.de/nachrichten-2026-11/70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm","entity":"wikidata:Q130146"}},{"name":"PR Newswire","kind":"person","role":"reporter","company":"Finanznachrichten.de","website":"https://finanznachrichten.de/","source":"https://www.finanznachrichten.de/nachrichten-2026-11/70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm","note":"Wrote: Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach","reason":"Reporter at Finanznachrichten.de; wrote “Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach” on 2026-11-18","group":"Reporters","add_url":"https://crm.joinhottub.com/relationships/add#name=PR%20Newswire&company=Finanznachrichten.de&website=https%3A%2F%2Ffinanznachrichten.de%2F&source=https%3A%2F%2Fwww.finanznachrichten.de%2Fnachrichten-2026-11%2F70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm&note=Wrote%3A%20Biocon%27s%20Pertuzumab%20Receives%20Marketing%20Authorization%20in%20EU%2C%20First%20Biosimilar%20Authorized%20Under%20EMA%27s%20New%20Tailored%20Clinical%20Approach","propose":{"name":"PR Newswire","kind":"person","reason":"Reporter at Finanznachrichten.de; wrote “Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach” on 2026-11-18","requestId":"news:n_mm4ydohuwbcrwduqtyta:Reporter:60fefb53:f94d4865","company":"Finanznachrichten.de","website":"https://finanznachrichten.de/","sourceUrl":"https://www.finanznachrichten.de/nachrichten-2026-11/70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm"}},{"name":"Finanznachrichten.de","kind":"organization","role":"outlet","website":"https://finanznachrichten.de/","entity":"wikidata:Q1408247","source":"https://www.finanznachrichten.de/nachrichten-2026-11/70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm","note":"Published: Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach (2026-11-18)","reason":"Published “Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach” on 2026-11-18","group":"Outlet","add_url":"https://crm.joinhottub.com/relationships/add#name=Finanznachrichten.de&kind=organization&website=https%3A%2F%2Ffinanznachrichten.de%2F&source=https%3A%2F%2Fwww.finanznachrichten.de%2Fnachrichten-2026-11%2F70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm&entity=wikidata%3AQ1408247&note=Published%3A%20Biocon%27s%20Pertuzumab%20Receives%20Marketing%20Authorization%20in%20EU%2C%20First%20Biosimilar%20Authorized%20Under%20EMA%27s%20New%20Tailored%20Clinical%20Approach%20%282026-11-18%29","propose":{"name":"Finanznachrichten.de","kind":"organization","reason":"Published “Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach” on 2026-11-18","requestId":"news:n_mm4ydohuwbcrwduqtyta:wikidata:Q1408247:a5e31cc5","website":"https://finanznachrichten.de/","sourceUrl":"https://www.finanznachrichten.de/nachrichten-2026-11/70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm","entity":"wikidata:Q1408247"}}],"someone_else":{"source":"https://www.finanznachrichten.de/nachrichten-2026-11/70166972-biocon-s-pertuzumab-receives-marketing-authorization-in-eu-first-biosimilar-authorized-under-ema-s-new-tailored-clinical-approach-008.htm","note":"In the news: Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach (Finanznachrichten.de, 2026-11-18)"},"crm":{"name":"CRM by Hottub","add":"Open add_url in a browser: CRM by Hottub's add form, filled in. Nothing is saved until the person presses Add.","mcp":"https://crm.joinhottub.com/api/crm/mcp","tool":"propose_relationship","propose":"If you're connected to CRM by Hottub's MCP server with proposal access, call propose_relationship with `propose` as its arguments. An owner approves it before anything is added. Keep the arguments as given: retries reuse requestId."}}